OTCEquity is a premier site for updated news and financial information regarding penny stocks and small cap companies. We offer a free newsletter, articles about penny stock trading, otc bulletin board analytical data and original news stories about the penny stock companies you are interested in.

Registration to our newsletter is FREE, Join today by entering your email below!

Tag Archives: biopharmaceutical

Has too Much Gone Wrong for MultiCell Technologies, Inc. (PINKSHEETS: MCET) to Regain Footing?

On Tuesday shares of MultiCell Technologies, Inc. (PINKSHEETS: MCET) opened at 0.0034, a nice jump from their previous close of 0.0020, but the day would offer even more surprises for shareholders as the biopharmaceutical company surged to a high of … Continue reading

Posted in Uncategorized | Tagged , , , , , , | Leave a comment

Can Dynavax Technologies Corporation (NASDAQ: DVAX) Overcome Safety Questions with Hepatitis B Vaccine and Get FDA Approval?

After sinking to a 52-week low of 2.22 on November 16, 2012 following an FDA Advisory Committee’s opinion that the data they reviewed regarding the hepatitis-B vaccine Heplisav was insufficient to demonstrate safety shares of Dynavax Technologies Corporation (NASDAQ: DVAX) … Continue reading

Posted in Articles, NASDAQ | Tagged , , , , , , , , | Leave a comment

Can Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM) Advance Cancer Drug into Phase III Trial Following Internal Review?

An internal review prompted by the discovery of vial coding discrepancies while preparing for an end of Phase II meeting with the FDA may have saved Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM) as shares of the biopharmaceutical company that develops first-in-class … Continue reading

Posted in Articles, NASDAQ | Tagged , , , , , , , | Leave a comment

Lexicon Pharmaceuticals (NASDAQ: LXRX) Looking at 2013 as Year of Opportunity for Drug Candidates

Trading volume in Lexicon Pharmaceuticals (NASDAQ: LXRX) spiked on Monday, closing the last trading day of 2012 with more than 6.7 million shares moving hands while the share price of the biopharmaceutical company, which focuses on discovering breakthrough treatments for … Continue reading

Posted in Articles, NASDAQ | Tagged , , , , , , , , | Leave a comment

Can Dynavax Technologies Corp. (NASDAQ: DVAX) Overcome FDA Setback for HEPLISAV?

Shares of Dynavax Technologies Corp. (NASDAQ: DVAX) have been getting pounded on Friday following yesterday’s announcement that their lead product candidate HEPLISAV, an adult hepatitis B vaccine, failed to gain the support of an FDA advisory committee concerning safety issues. … Continue reading

Posted in Articles, NASDAQ | Tagged , , , , , , , , , | Leave a comment

Can Pain Therapeutics Inc. (NASDAQ: PTIE) Overcome Setback Related to Remoxy?

Shares of Pain Therapeutics Inc. (NASDAQ: PTIE) continue to take a beating following news that their lead drug candidate Remoxy will be subjected to further tests before Pfizer agrees to seek FDA approval for the pain medication. Just yesterday shares … Continue reading

Posted in Articles, NASDAQ | Tagged , , , , , , , , | Leave a comment

Busy Month for BioLine RX Ltd. (NASDAQ: BLRX) Has Biopharmaceutical Development Company on the Radar of Investors

After closing last week at 2.32 shares of BioLine RX Ltd. (NASDAQ: BLRX) jumped to a high of 2.85 on Monday with heavy trading volume following news that the biopharmaceutical development company had received from the United States Patent and … Continue reading

Posted in Articles, NASDAQ | Tagged , , , , , , , , | Leave a comment

Will Top-Line Results in PDP Study Push ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) to New Heights?

To say that ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) has been building momentum since their September 5, 2012 press release regarding the completion of enrollment in its ongoing pivotal Phase III trial with pimavanserin in patients with Parkinson’s disease psychosis (PDP) … Continue reading

Posted in Articles, NASDAQ | Tagged , , , , , , , | Leave a comment

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) Gaining Momentum Following Reverse Stock Split

Shares of Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) have spiked to a high of 5.47 today and while they have slipped back down around the 5.24 level they are considerably higher than the 4.04 at which they opened the day. Along … Continue reading

Posted in Articles, NASDAQ | Tagged , , , , , , , , | Leave a comment

With Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) Affecting Reverse Stock Split Have They Bought Enough Time for Treatment of AML in Elderly?

Needing to boost their share price to satisfy the 1.00 minimum bid price requirement for continued listing on the NASDAQ Global Market, Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) announced a 1-for-7 reverse stock split on Friday and on Monday that split … Continue reading

Posted in Articles, NASDAQ | Tagged , , , , , , , , | Leave a comment